Eli Lilly Q3 earnings eyed for insights into drug pricing policies, obesity and diabetes drug performanceProactive Investors • 10/20/25
J.L. Bainbridge Buys $45 Million in Eli Lilly Stock Despite Price-Pressure FearsThe Motley Fool • 10/20/25
Investment Advisor Goes All-In on Big Pharma Stock to the Tune of $1.07 Billion, According to Recent FilingThe Motley Fool • 10/19/25
NVO and LLY Stocks Slide as Trump Signals Price Cuts for GLP-1 DrugsZacks Investment Research • 10/17/25
Trump Pledges To Cut Obesity Drug Prices. Novo Nordisk, Eli Lilly Stocks Dive.Investors Business Daily • 10/17/25
Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs?Benzinga • 10/17/25
Novo Nordisk, Eli Lilly shares drop as Trump promises lower weight loss drug pricesProactive Investors • 10/17/25
Lilly's Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatmentPRNewsWire • 10/17/25
Eli Lilly, Novo Nordisk Stocks Drop After Trump's Ozempic Price Comment. What to Know.Barrons • 10/17/25
Eli Lilly vs. Viking Therapeutics Stock: Which Is the Best Growth Opportunity, According to Wall Street?The Motley Fool • 10/17/25
How Will Mounjaro and Zepbound Sales Aid Lilly's Upcoming Q3 Results?Zacks Investment Research • 10/16/25
Lilly confirms date and conference call for third-quarter 2025 financial results announcementPRNewsWire • 10/16/25